Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

2.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
3.

Advances in pneumococcal vaccines: what are the advantages for the elderly?

Vila-Córcoles A.

Drugs Aging. 2007;24(10):791-800. Review.

PMID:
17896829
4.

The worldwide impact of the seven-valent pneumococcal conjugate vaccine.

Fitzwater SP, Chandran A, Santosham M, Johnson HL.

Pediatr Infect Dis J. 2012 May;31(5):501-8. doi: 10.1097/INF.0b013e31824de9f6.

PMID:
22327872
5.

Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States.

Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP.

MBio. 2011 Jan 25;2(1):e00309-10. doi: 10.1128/mBio.00309-10.

6.

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, Puig-Barberá J, Lluch-Rodrigo JA, Pastor-Villalba E.

Vaccine. 2011 Dec 6;29(52):9640-8. doi: 10.1016/j.vaccine.2011.10.038. Epub 2011 Oct 24.

PMID:
22027484
7.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
8.

Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

King JC Jr, Vink PE, Farley JJ, Parks M, Smilie M, Madore D, Lichenstein R, Malinoski F.

Pediatr Infect Dis J. 1996 Mar;15(3):192-6.

PMID:
8852905
9.

A population-based analysis of pneumococcal disease mortality in California, 1989-1998.

Redelings MD, Sorvillo F, Simon P.

Public Health Rep. 2005 Mar-Apr;120(2):157-64.

10.

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010.

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060. Epub 2012 Apr 11.

PMID:
22504662
11.
12.

Physician perspectives regarding pneumococcal conjugate vaccine.

Schaffer SJ, Szilagyi PG, Shone LP, Ambrose SJ, Dunn MK, Barth RD, Edwards K, Weinberg GA, Balter S, Schwartz B.

Pediatrics. 2002 Dec;110(6):e68.

PMID:
12456935
14.

A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN; Infectious Disease Clinical Research Program HIV Working Group.

J Infect Dis. 2010 Oct 1;202(7):1114-25. doi: 10.1086/656147.

15.

Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006.

Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D.

Euro Surveill. 2008 Aug 28;13(35). pii: 18962.

16.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

17.

Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia.

Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC.

J Infect Dis. 2008 Oct 1;198(7):1019-27. doi: 10.1086/591629.

18.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group.

Clin Infect Dis. 2006 Oct 1;43(7):860-8. Epub 2006 Aug 21.

19.

Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.

Harboe ZB, Valentiner-Branth P, Benfield TL, Christensen JJ, Hjuler T, Kaltoft M, Krogfelt KA, Lambertsen L, Konradsen HB.

Vaccine. 2008 Jul 4;26(29-30):3765-71. doi: 10.1016/j.vaccine.2008.04.040. Epub 2008 May 5.

PMID:
18513840
20.

The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence?

Musher DM, Sampath R, Rodriguez-Barradas MC.

Clin Infect Dis. 2011 Mar 1;52(5):633-40. doi: 10.1093/cid/ciq207.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk